A study to compare the safety and efficacy of Amitriptyline and Gabapentin in Herpes zoster associated pain.

Effectiveness and Safety of Amitriptyline vs. Gabapentin in Zoster-Associated Pain: An Investigator-Blind Randomized Controlled Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2015/09/006159

Enrollment

Registered

2015-09-03

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Zoster associated pain

Interventions

Intervention1: Amitriptyline: 25 mg once daily orally for 12 weeks Control Intervention1: Gabapentin: 100 mg thrice daily orally for 12 weeks

Eligibility

Inclusion criteria

Inclusion criteria: i. The patients presenting with active herpes zoster lesions with associated ZAP. ii. Patients who give their informed consent. iii. Age group: 18 years to 80 years

Exclusion criteria

Exclusion criteria: i. Patients not giving their informed consent. ii. Pregnant or lactating women iii. Patients who have participated in a clinical trial in the past 3 months

Design outcomes

Primary

Measure	Time frame
McGill pain questionnaire (MPQ)Timepoint: baseline, 1 week, 4 weeks, 12 weeks	—

Secondary

Measure	Time frame
Dermatologic Life Quality Index: Vernacular validated version usedTimepoint: baseline, 1 week, 4 weeks, 12 weeks;Patients Global Assesment (PGA) Scale: Score of 0-10 (10- maximum pain; 0- No pain) Timepoint: baseline, 1 week, 4 weeks, 12 weeks	—

Countries

India

Contacts

Public ContactAmrita Sil

Medical College Kolkata

drdasnilay@gmail.com9433394148

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026